A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis
Public ClinicalTrials.gov record NCT01292187. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Clinical Trial Evaluating the Safety and Efficacy of Oral Recombinant Salmon Calcitonin (rsCT) in the Prevention of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study was to evaluate the efficacy of oral calcitonin (rsCT)tablets in the prevention of bone loss in postmenopausal women with lower bone mineral density at increased risk of fracture. The secondary purpose of this study was to determine if there is any food effect by comparing the efficacy and safety of oral calcitonin tablets administered at dinner or at bedtime.
Study identification
- NCT ID
- NCT01292187
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 129 participants
Conditions and interventions
Conditions
Interventions
- Oral calcitonin at dinnertime Drug
- Oral placebo at dinnertime Drug
- Oral calcitonin at bedtime Drug
- Oral placebo at bedtime Drug
Drug
Eligibility (public fields only)
- Age range
- 45 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2010
- Primary completion
- Apr 30, 2012
- Completion
- Jun 30, 2012
- Last update posted
- Sep 11, 2014
2011 – 2012
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Diablo Clinical Research, Inc. | Walnut Creek | California | 94598 | — |
| Innovative Research of West Florida, Inc. | Clearwater | Florida | 33756 | — |
| Bethesda Health Research | Bethesda | Maryland | 20817 | — |
| Clinical Pharmacology Study Group | Worcester | Massachusetts | 01610 | — |
| Michigan Bone and Mineral Clinic | Detroit | Michigan | 48236 | — |
| The Osteoporosis Center at St. Luke's Hospital | Chesterfield | Missouri | 63107 | — |
| Comprehensive Clinical Research | Berlin | New Jersey | 08009 | — |
| University of Pittsburgh - Department of Neurology | Pittsburgh | Pennsylvania | 15213 | — |
| Puget Sound Osteoporosis Center | Seattle | Washington | 98144 | — |
| University of Wisconsin Hospital and Clinics | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01292187, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 11, 2014 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01292187 live on ClinicalTrials.gov.